ABIONYX Pharma SA (FRA:609)

Germany flag Germany · Delayed Price · Currency is EUR
3.690
-0.090 (-2.38%)
At close: Dec 4, 2025
200.49%
Market Cap 134.89M
Revenue (ttm) 4.33M
Net Income (ttm) -4.60M
Shares Out n/a
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 80
Open 3.690
Previous Close 3.780
Day's Range 3.690 - 3.690
52-Week Range 1.096 - 5.000
Beta n/a
RSI 41.39
Earnings Date Dec 24, 2025

About ABIONYX Pharma

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2005
Employees 51
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 609
Full Company Profile

Financial Performance

In 2024, ABIONYX Pharma's revenue was 4.55 million, a decrease of -1.92% compared to the previous year's 4.64 million. Losses were -4.38 million, 24.5% more than in 2023.

Financial Statements

News

There is no news available yet.